Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel treatments ...

In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to overlook the biotechnology sector. However, for investors willing to look beyond ...

CRISPR Therapeutics is targeting multiple difficult-to-treat diseases with several candidates. The company's shares could soar if it delivers consistent clinical and regulatory progress. However, the ...

Commodore Capital sold 1,850,000 shares of Centessa in the fourth quarter; the estimated trade value was $46.86 million. Meanwhile, the quarter-end position value decreased by $44.10 million, ...

DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, ...

(RTTNews) - Biotech and life sciences stocks have continued their strong momentum into 2026, with several profiled companies hitting fresh 52-week and all-time highs. Strategic financings, ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.76 per share a year ago. These ...

(RTTNews) - Kane Biotech Inc. (KNBIF) announced that the U.S. FDA has granted 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser, marking a key regulatory milestone for the ...

(RTTNews) - Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, Inc., announced that Cyprium has entered into a definitive agreement to sell its Rare Pediatric ...

VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This regulatory ...

FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, ...

In this podcast, Motley Fool analysts Karl Thiel, Tom King, and Tim Beyers discuss: Slow rolling chaos at the FDA and its effects on drug approvals. How to think about risk when investing in biotech.